… Board with Leaders in Inherited Retinal Disease and RNATherapy LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 … to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today …
ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.
… Trial enrollment continuing for three clinical stage RNA therapies in development for inherited retinal diseases, … (SAB) with leaders in inherited retinal disease and RNAtherapy. The SAB members are: James Shannon, MD, Chair of the …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … (SAB) with leaders in inherited retinal disease and RNAtherapy. In February, ProQR announced its participation in …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … 1b/2 trial results of the intravitreal sepofarsen RNAtherapy in LCA10 (encore presentations) Full-field stimulus …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
… on track to be reported in H2 2020; Three clinical stage RNA therapies in development for inherited retinal diseases, … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … “The visual field improvements observed indicate that RNAtherapy could potentially be used to treat early stage …